Waters Biosciences brings the former BD flow portfolio to ICCS 2026 under its new division

Waters completed its combination with BD's Biosciences & Diagnostic Solutions businesses on 9 February 2026 and created a Waters Biosciences division containing the former BD Biosciences portfolio.

At ICCS 2026, Waters Biosciences is presenting a connected flow cytometry stack that includes FACSLyric and FACSDuet for routine workflows, FACSDiscover A7 for higher-dimensional spectral analysis, FACSDiscover A8 with CellView imaging, Horizon reagents, Cytognos MRD research workflows, Infinicyt and FlowJo software.

CFCM explainer — portfolio architecture

Routine clinical workflow → spectral analysis → imaging flow → software/data analysis.

Source/credit: CFCM market-architecture explainer based on the current Waters Biosciences ICCS 2026 portfolio page, checked 4 October 2026. Alt text: four-stage diagram showing routine clinical flow, spectral analysis, imaging flow and downstream software under Waters Biosciences.

This is a company and portfolio signal, not evidence that every named product has the same regulatory status or intended use.

Conference positioning such as a connected vision for clinical flow cytometry is corporate messaging, not independent evidence of analytical superiority. Product regulatory status remains product- and jurisdiction-specific. The ICCS page mixes routine clinical systems with research-use technologies, so CFCM does not transfer clinical status from one product to another.

For laboratories and competitors, the important market change is organizational: one of the largest installed flow-cytometry portfolios is now being presented as part of Waters Biosciences rather than as a standalone BD Biosciences business. That can affect future software integration, portfolio bundling, service strategy and the way laboratories compare complete ecosystems instead of individual cytometers.